SELLAS Life Sciences shares plunge 19%: What triggered the sharp sell-off?

Economic Times - Nov 20, 2026

SELLAS Life Sciences shares plunged nearly 20% after the biotechnology company priced a $150 million public offering at $13 per share, a discount of around 28% to its previous close. The sell-off followed a sharp rally triggered by positive Phase 3 REGAL trial results for its experimental leukemia vaccine.

Read full article
More News
Copyright © 2015 - 2026 The Financial Capital.

All Rights Reserved.

Subscribe Now!

About Us

The Financial Capital is your independent source for finance information and advice. We provide insights and offer advice from financial experts so you can make the best decisions.